689 -- A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes. | Poliscope

A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.

689

118th Congress

Crime and Law Enforcement

In Committee

A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.

Legislative Progress

✓

Introduced

2

Committee

3

Floor Vote

4

Other Chamber

5

Enacted

Introduced

March 7, 2023

Latest Action

March 7, 2023

Primary Sponsor

Cory A. BookerDemocratic(NJ)

Momentum (last 30 days)

0

score

0 actions · 0 new cosponsors · 0 votes

Speed vs cohort

0pct

0d open

vs 5,649 other S bills in the 118th — cohort avg 33d

Summary

No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.

Lobbying filings that explicitly cite this bill (18)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (4)

DB3, LLC (FKA THE DASCHLE GROUP) (5)BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ (5)HOOPER, LUNDY & BOOKMAN, P.C. (2)THE VOGEL GROUP (4)

REASON FOR HOPEclient→DB3, LLC (FKA THE DASCHLE GROUP)

2024 · fourth_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy

Client expense: Not reported · Firm income: $30,000

Actions (2)

March 7, 2023

Read twice and referred to the Committee on the Judiciary.

March 7, 2023

Introduced in Senate

Committees

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	March 7, 2023

Text Versions

Version	Date	Links
Introduced in Senate	March 7, 2023	XML

Cosponsors (5)

Name	Party	State
John Boozman	Republican	AR
John Fetterman	Democratic	PA
Kyrsten Sinema	Independent	AZ

Related Bills (1)

Bill	Congress	Relationship
HR 1393	118th	Related bill

Similar Bills (AI)

Bills with similar content found using semantic analysis.

118th

97%

To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.

118th

80%

A bill to amend the Controlled Substances Act to fix a technical error in the definitions.

118th

74%

To amend the Controlled Substances Act to fix a technical error in the definitions.

Sources: Congress.gov

Show 14 more cited filings

REASON FOR HOPEclient→DB3, LLC (FKA THE DASCHLE GROUP)

2024 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy

Client expense: Not reported · Firm income: $30,000

S.689

mr CHARLES PANFIL ms GRACE TEETERS

Government targets: HOUSE OF REPRESENTATIVES, SENATE

BRAINFUTURESclient→HOOPER, LUNDY & BOOKMAN, P.C.

2024 · third_quarter · Medical/Disease Research/Clinical Labs

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, issues related to medical adoption of psychedelic drugs and therapies, issues related to equitable access to psychedelic drugs and therapies; S. 689/H.R. 1393, A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.

Client expense: Not reported · Firm income: $20,000

S. 689

Government targets: HOUSE OF REPRESENTATIVES, SENATE

BRAINFUTURESclient→HOOPER, LUNDY & BOOKMAN, P.C.

2024 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, issues related to medical adoption of psychedelic drugs and therapies, issues related to equitable access to psychedelic drugs and therapies; S. 689/H.R. 1393, A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.

Client expense: Not reported · Firm income: $20,000

S. 689

Government targets: HOUSE OF REPRESENTATIVES, SENATE

VETERAN MENTAL HEALTH LEADERSHIP COALITIONclient→THE VOGEL GROUP

2024 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lobbied to garner support and cosponsors on H.R. 1393 and S. 689, The Breakthrough Therapies Act

Client expense: Not reported · Firm income: $15,000

S. 689

BOBBY CUNNINGHAM mr MATTHEW KEELEN mr NIKHIL DHINGRA ms ALLISON SMITH

Government targets: HOUSE OF REPRESENTATIVES, SENATE

REASON FOR HOPEclient→DB3, LLC (FKA THE DASCHLE GROUP)

2024 · second_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy

Client expense: Not reported · Firm income: $20,000

S.689

mr CHARLES PANFIL ms GRACE TEETERS

Government targets: HOUSE OF REPRESENTATIVES, SENATE

VETERAN MENTAL HEALTH LEADERSHIP COALITIONclient→THE VOGEL GROUP

2024 · second_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lobbied to garner support and cosponsors on H.R. 1393 and S. 689, The Breakthrough Therapies Act

Client expense: Not reported · Firm income: $15,000

S. 689

BOBBY CUNNINGHAM mr MATTHEW KEELEN mr NIKHIL DHINGRA

Government targets: HOUSE OF REPRESENTATIVES, SENATE

REASON FOR HOPEclient→DB3, LLC (FKA THE DASCHLE GROUP)

2024 · first_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy

Client expense: Not reported · Firm income: $10,000

S.689

THOMAS DASCHLE mr CHARLES PANFIL

Government targets: HOUSE OF REPRESENTATIVES, SENATE

VETERAN MENTAL HEALTH LEADERSHIP COALITIONclient→THE VOGEL GROUP

2024 · first_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lobbied to garner support and cosponsors on H.R. 1393 and S. 689, The Breakthrough Therapies Act

Client expense: Not reported · Firm income: $15,000

S. 689

mr MATTHEW KEELEN mr NIKHIL DHINGRA

Government targets: HOUSE OF REPRESENTATIVES, SENATE

REASON FOR HOPEclient→DB3, LLC (FKA THE DASCHLE GROUP)

2024 · first_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Breakthrough Therapies Act (H.R.1393/S.689), psychedelics research and treatment policy, in general.

Client expense: Not reported · Firm income: Not reported

S.689

THOMAS DASCHLE mr CHARLES PANFIL

REASON FOR HOPEclient→BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ

2024 · first_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy

Client expense: Not reported · Firm income: $10,000

S.689

THOMAS DASCHLE mr CHARLES PANFIL

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

REASON FOR HOPEclient→BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ

2023 · fourth_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy

Client expense: Not reported · Firm income: $20,000

S.689

mr CHARLES PANFIL

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

REASON FOR HOPEclient→BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ

2023 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy

Client expense: Not reported · Firm income: $20,000

S.689

mr CHARLES PANFIL

Government targets: HOUSE OF REPRESENTATIVES, SENATE

REASON FOR HOPEclient→BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ

2023 · second_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy

Client expense: Not reported · Firm income: $10,000

S.689

mr CHARLES PANFIL

Government targets: HOUSE OF REPRESENTATIVES, SENATE

REASON FOR HOPEclient→BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ

2023 · second_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Breakthrough Therapies Act (H.R.1393/S.689), psychedelics research and treatment policy, in general

Client expense: Not reported · Firm income: Not reported

S.689

mr CHARLES PANFIL